QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 ...

Qiagen N.V. (NYSE:QGEN) is one of the 10 potential takeover targets with strong price momentum. The latest relevant ...

Qiagen is moving into syndromic testing for bloodstream infections with the launch of the Netherlands-based diagnostics maker ...

Qiagen’s next-generation sequencing tests are already used to look for genetic variants that may shed light on an individual’s specific case of cancer and potential treatment options, but the ...

Simplified and accelerated research workflow including high-quality DNA extraction kits, library preparation for whole genome metagenomics, and user-friendly bioinformatics analysis // Workflow ...

Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome ...

Fintel reports that on April 14, 2026, Barclays downgraded their outlook for Qiagen N.V. (NYSE:QGEN) from Overweight to Equal ...

ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through ...

Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028 VENLO, Netherlands-- ...

Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases Strengthens QIAGEN Digital Insights offering for small and mid-sized labs worldwide ...

REDWOOD CITY, Calif. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its decision-support software platform QIAGEN Clinical Insights (QCI) ...